{"id":40095,"date":"2025-12-02T05:00:00","date_gmt":"2025-12-01T22:00:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=40095"},"modified":"2025-12-02T05:00:00","modified_gmt":"2025-12-01T22:00:00","slug":"ziwig-endotest-scientific-validation-published-in-nejm-evidence","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=40095","title":{"rendered":"Ziwig Endotest\u00ae: Scientific Validation Published in NEJM Evidence"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2835260\/Ziwig_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">LYON, France<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Dec. 2, 2025<\/span><\/span> \/PRNewswire\/ &#8212; NEJM Evidence, a journal of the New England Journal of Medicine Group, has published an article titled &#8220;Validation of a Saliva microRNA Signature for Endometriosis,&#8221; dedicated to the saliva-based diagnostic test developed by Ziwig.<\/p>\n<p>The publication reports the results of a prospective, independent,\u00a0multicenter clinical study conducted in <span class=\"xn-location\">France<\/span>. The study enrolled 971 symptomatic women aged 18 to 43 years across 17 public and private hospitals.<\/p>\n<p><b>High-performance saliva-based diagnosis<\/b><\/p>\n<p>The Ziwig Endotest\u00ae was evaluated through the analysis of 109 salivary microRNAs, combining next-generation sequencing (NGS) with artificial intelligence. Diagnostic interpretations were performed blindly, without prior knowledge of the patients&#8217; clinical status, ensuring full methodological independence and robustness.<\/p>\n<p>The NEJM Evidence publication highlights exceptional diagnostic performance:<\/p>\n<ul type=\"disc\">\n<li><b>Sensitivity:<\/b><b> 97.3%<\/b><\/li>\n<li><b>Specificity:<\/b><b> 94.1%<\/b><\/li>\n<li><b>Overall accuracy:<\/b><b> 96.6%<\/b><\/li>\n<li><b>Positive predictive value:<\/b><b> 98.2%<\/b><\/li>\n<li><b>Negative predictive value:<\/b><b> 91.3%<\/b><\/li>\n<\/ul>\n<p>These results show that<b> more than 96 out of 100 women receive an accurate diagnostic result with Ziwig Endotest\u00ae<\/b>. Performance remained consistent across all subgroups, regardless of hormonal treatment, analgesic use, inclusion site, or sequencing conditions, confirming the reliability and reproducibility of the test in real-world settings.<\/p>\n<p><b>Now available for routine prescription in clinical practice<\/b><\/p>\n<p>Within the framework of the French national early access program for breakthrough technologies (Forfait Innovation), Ziwig Endotest\u00ae is now reimbursed and available on medical prescription in 100 hospitals across <span class=\"xn-location\">France<\/span>.<\/p>\n<p>It is indicated for women aged 18 to 43 years with chronic pelvic pain suggestive of endometriosis, when imaging results are normal or inconclusive. The test can be prescribed outside any research study, providing women with rapid, non-invasive, and accurate access to diagnosis.<br \/><b><br \/>A major advance for women&#8217;s health<\/b><\/p>\n<p>Endometriosis affects around 10% of women of reproductive age, with diagnostic delays often exceeding seven years. The validation and clinical deployment of Ziwig Endotest\u00ae mark a major step forward toward earlier, simpler, and more equitable diagnosis.<\/p>\n<p>&#8220;<i>This publication in NEJM Evidence is a major step forward for science and for women affected by endometriosis. We are deeply grateful to all the women, hospitals, and healthcare professionals whose commitment and support have been essential in bringing this innovation to patients,&#8221;<\/i> said <span class=\"xn-person\">Yahya El Mir<\/span>, Founder and President of Ziwig.<\/p>\n<p>For more information:\u00a0<a href=\"https:\/\/www.ziwig.com\/\" target=\"_blank\" rel=\"nofollow\">www.ziwig.com<\/a><\/p>\n<p>Contact\u00a0presse \u2013 Finn Partners<br \/>Marie-H\u00e9l\u00e8ne Coste &amp; Aur\u00e9lia Adloff<br \/>06 20 89 49 03 \/ 06 89 38 94 70<br \/><a href=\"mailto:sante@finnpartners.com\" target=\"_blank\" rel=\"nofollow\">sante@finnpartners.com<\/a><\/p>\n<p>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2835260\/Ziwig_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">LYON, France<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Dec. 2, 2025<\/span><\/span> \/PRNewswire\/ &#8212; NEJM Evidence, a journal of the New England Journal of Medicine Group, has published an article titled &#8220;Validation of a Saliva microRNA Signature for Endometriosis,&#8221; dedicated to the saliva-based diagnostic test developed by Ziwig.<\/p>\n<p>The publication reports the results of a prospective, independent,\u00a0multicenter clinical study conducted in <span class=\"xn-location\">France<\/span>. The study enrolled 971 symptomatic women aged 18 to 43 years across 17 public and private hospitals.<\/p>\n<p><b>High-performance saliva-based diagnosis<\/b><\/p>\n<p>The Ziwig Endotest\u00ae was evaluated through the analysis of 109 salivary microRNAs, combining next-generation sequencing (NGS) with artificial intelligence. Diagnostic interpretations were performed blindly, without prior knowledge of the patients&#8217; clinical status, ensuring full methodological independence and robustness.<\/p>\n<p>The NEJM Evidence publication highlights exceptional diagnostic performance:<\/p>\n<ul type=\"disc\">\n<li><b>Sensitivity:<\/b><b> 97.3%<\/b><\/li>\n<li><b>Specificity:<\/b><b> 94.1%<\/b><\/li>\n<li><b>Overall accuracy:<\/b><b> 96.6%<\/b><\/li>\n<li><b>Positive predictive value:<\/b><b> 98.2%<\/b><\/li>\n<li><b>Negative predictive value:<\/b><b> 91.3%<\/b><\/li>\n<\/ul>\n<p>These results show that<b> more than 96 out of 100 women receive an accurate diagnostic result with Ziwig Endotest\u00ae<\/b>. Performance remained consistent across all subgroups, regardless of hormonal treatment, analgesic use, inclusion site, or sequencing conditions, confirming the reliability and reproducibility of the test in real-world settings.<\/p>\n<p><b>Now available for routine prescription in clinical practice<\/b><\/p>\n<p>Within the framework of the French national early access program for breakthrough technologies (Forfait Innovation), Ziwig Endotest\u00ae is now reimbursed and available on medical prescription in 100 hospitals across <span class=\"xn-location\">France<\/span>.<\/p>\n<p>It is indicated for women aged 18 to 43 years with chronic pelvic pain suggestive of endometriosis, when imaging results are normal or inconclusive. The test can be prescribed outside any research study, providing women with rapid, non-invasive, and accurate access to diagnosis.<br \/><b><br \/>A major advance for women&#8217;s health<\/b><\/p>\n<p>Endometriosis affects around 10% of women of reproductive age, with diagnostic delays often exceeding seven years. The validation and clinical deployment of Ziwig Endotest\u00ae mark a major step forward toward earlier, simpler, and more equitable diagnosis.<\/p>\n<p>&#8220;<i>This publication in NEJM Evidence is a major step forward for science and for women affected by endometriosis. We are deeply grateful to all the women, hospitals, and healthcare professionals whose commitment and support have been essential in bringing this innovation to patients,&#8221;<\/i> said <span class=\"xn-person\">Yahya El Mir<\/span>, Founder and President of Ziwig.<\/p>\n<p>For more information:\u00a0<a href=\"https:\/\/www.ziwig.com\/\" target=\"_blank\" rel=\"nofollow\">www.ziwig.com<\/a><\/p>\n<p>Contact\u00a0presse \u2013 Finn Partners<br \/>Marie-H\u00e9l\u00e8ne Coste &amp; Aur\u00e9lia Adloff<br \/>06 20 89 49 03 \/ 06 89 38 94 70<br \/><a href=\"mailto:sante@finnpartners.com\" target=\"_blank\" rel=\"nofollow\">sante@finnpartners.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-40095","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/40095","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40095"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/40095\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40095"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40095"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}